OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review	43
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	37
Advances in myelodysplastic syndromes: promising novel agents and combination strategies	36
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	33
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms	28
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly	25
An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: ‘bridging the gap between laboratory data and patient related outcomes’	22
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	21
The development of a home-based therapeutic platform for multiple myeloma	20
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?	20
Post-COVID-19 hematologic complications: a systematic review	19
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds	18
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review	17
Exploring health disparities in diagnosing multiple myeloma	17
The promise of novel treatments for severe chronic neutropenia	16
National strategic advocacy to manage patients with inherited bleeding disorders in low and lower-middle income countries	16
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	15
Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis	15
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection	15
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review	14
Computational modeling – an approach to the development of blood grouping reagents	14
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	13
Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura	13
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	13
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	12

Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts	12
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura	12
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	11
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	10
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	10
Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria	10
Factors associated with blood pressure variation in sickle cell disease patients: a systematic review and meta-analyses	10
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?	10
Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and th	10
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	10
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	9
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	9
BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events	9
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	9
Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplan	9
How low risk are low risk myelodysplastic syndromes?	9
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	8
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	8
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	8
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia	8
An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis	8
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	8
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide	8
CD123-targeted therapy in acute myeloid leukemia	8
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	8
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	7
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia	7
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma	7
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma	7
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	7
Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies	7
Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?	7
Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis	7
Do we need more guidance on thrombophilia testing? Challenges and special considerations	7
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	7
Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections	7
What is the future of digital tools to help manage pain in sickle cell disease patients?	7
Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future	7
Inhibitor eradication and treatment for acquired hemophilia A	7
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	7
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	7
Effect of days of age at first blood transfusion on intraventricular hemorrhage in very low and extremely low birth weight infants	6
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	6
The medication usage pattern and prevalence of polypharmacy among patients with sickle cell disease: a population-based study in southern Iran	6
Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence	6
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease	6
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	6
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI	6
Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma	6
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions	6

A comprehensive review on gelatinous transformation of the bone marrow	6
Identifying prognostic gene panels in acute myeloid leukemia	6
Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system	6
Intra-articular injection of platelet-rich plasma in patients with hemophilia and painful knee joint cartilage degeneration	5
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	5
Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review	5
Overexpression of cancerous inhibitor ofPP2A (CIP2A) in acute myeloid leukemia	5
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	5
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	5
New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond	5
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations	5
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges	5
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	5
Targeting von Willebrand disease: the current status and future directions of management therapies	5
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	5
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	5
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	5
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	5
Managing complications secondary to Waldenström’s macroglobulinemia	5
Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma	5
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation	5
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	5
Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings?	4
Fetal anemia in monochorionic twins: a review on diagnosis, management, and outcome	4
Early diagnosis of persons with von Willebrand disease using a machine learning algorithm and real-world data	4
Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings	4
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	4
Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias	4
Outcome measures in hemophilia: current and future perspectives	4
Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding	4
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	4
Foreword: a special focus on bleeding disorders	4
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma	4
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	4
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	4
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients	4
Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents	4
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	4
How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies	4
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	4
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	4
Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint	4
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)	4
Genome- and transcriptome-wide association studies show that pulmonary embolism is associated with bone-forming proteins	4
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment?	4